High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension

Journal of Pathology

Volumn 185, Issue 3, 1998, Pages 313-318

  Mason, Nicola A ^a   Springall, David R ^d   Burke, Margaret ^b   Pollock, Jennifer ^c   Mikhail, Ghada ^b   Yacoub, Magdi H ^b   Polak, Julia M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAREFIELD HOSPITAL   (United Kingdom)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d NONE

Author keywords

Immunohistochemistry; Nitric oxide synthase; Pulmonary hypertension

Indexed keywords

NITRIC OXIDE SYNTHASE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SCHOOL CHILD; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADULT; ARTERIOLES; CHILD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; MALE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PULMONARY ARTERY; RETROSPECTIVE STUDIES;

EID: 0031856005     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199807)185:3<313::AID-PATH93>3.0.CO;2-8     Document Type: Article

References (35)

1. Harris P, Heath D. The Human Pulmonary Circulation: its Form and Function in Health and Disease. Edinburgh: Churchill Livingstone, 1986: 247-272.
2. Hatano S, Strasser T. Primary Pulmonary Hypertension. Report of a WHO Meeting. Geneva: World Health Organization, 1975.
3. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8: 2129-2138.
4. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, pharmacology. Pharmacol Rev 1991; 43: 109-142.
5. Adnot S, Raffestin B, Eddahibi S, Braquet P, Chabrier PE. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest 1991; 87: 155-162.
6. Isaacson TC, Hampl V, Weir EK, Nelson DP, Archer SL. Increased endothelium-derived NO in hypertensive pulmonary circulation of chronically hypoxic rats. J Appl Physiol 1994; 76: 933-940.
7. McQuillan LP, Leung GK, Marsden PA, Kostyk SK, Kourembanas S. Hypoxia inhibits expression of eNOS via transcriptional and post-transcriptional mechanisms. Am J Physiol 1994; 267: H1921-1927.
8. Xue C, Rengasamy A, Le Cras TD, Koberna PA, Dailey GC, Johns RA. Distribution of NOS in normoxic vs. hypoxic rat lung: upregulation of NOS by chronic hypoxia. Am J Physiol 1994: 267: L667-678.
9. Mannan MM, Springall DR, Enard C, et al. Decreased endothelium-dependent pulmonary vasodilator effect of calcitonin gene-related peptide in hypoxic rats contrasts with increased binding sites. Eur Respir J 1995; 8: 2029-2037.
10. Shaul PW, North AJ, Brannon TS, et al. Prolonged in vivo hypoxia enhances nitric oxide synthase type I and type III gene expression in adult rat lung. Am J Respir Cell Mol Biol 1995; 13: 167-174.
11. Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991; 324: 1539-1547.
12. Brett SJ, Gibbs SR, Pepper JR, Evans TW. Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension. Thorax 1996; 51: 89-91.
13. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
14. Xue C, Johns RA. Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 1642-1644.
15. Springall DR, Riveros-Moreno V, Buttery L, et al. Immunological detection of nitric oxide synthase(s) in human tissues using heterologous antibodies suggesting different isoforms. Histochemistry 1995; 98: 259-266.
16. Pollock JS, Nakane M, Buttery LD, et al. Characterization and localization of endothelial nitric oxide synthase using specific monoclonal antibodies. Am J Physiol 1993; 265: C1379-1387.
17. Buttery LDK, McCarthy A, Springall DR. et al. Endothelial nitric oxide synthase in the human placenta: regional distribution and proposed regulatory role at the feto-maternal interface. Placenta 1994; 15: 257-265.
18. Buttery LDK. Nitric oxide synthase isoenzymes in healthy and diseased mammalian tissues: an immunocytochemical study. PhD Thesis. University of London, 1996.
19. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-285.
20. Bankfalvi A, Navabi H, Bier B, Böcker W, Jasani B, Schmid KW. Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry. J Pathol 1994; 174: 223-228.
21. Wagenwoort CA, Mooi WJ. Biopsy Pathology of the Pulmonary Vasculature. London: Chapman & Hall, 1989.
22. Rutishauser E, Blanc W. Anastomoses artérioveineuses glomiques du poumon avec syndrome d'insuffisance droite et cyanose. Schweiz Z Allg Pathol Bakteriol 1950; 13: 61-65.
23. Spencer H. Primary pulmonary hypertension and related vascular changes in the lungs. J Pathol Bacterial 1950; 62: 489-493.
24. Jewett JF, Ober WB. Primary pulmonary hypertension as a cause of maternal death. Am J Obstet Gynecol 1956; 71: 1335-1341.
25. Jamison BM, Michel RP. Different distribution of plexiform lesions in primary and secondary pulmonary hypertension. Hum Pathol 1995; 26: 987-993.
26. Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis 1986; 134: 342-346.
27. Rich S, Brundage BH. High dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary artery pressure and regression of right ventricular hypertrophy. Circulation 1987; 76: 135-141.
28. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989; 140: 1623-1630.
29. Rubin LJ, Mendoza J, Hood M. et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomised trial. Ann Intern Med 1990; 112: 485-491.
30. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
31. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
32. Cacoub P, Karmocchkine M, Dorent R, et al. Plasma levels of thrombomodulin in pulmonary hypertension. Am J Med 1996; 101: 160-164.
33. Marsden PA, Heng HH, Scherer SW, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478-17488.
34. Nishida K, Harrison DG, Navas JP, et al. Molecular cloning and characterisation of the constitutive bovine aortic endothelial nitric oxide synthase. J Clin Invest 1992; 90: 2092-2096.
35. Arnal JF, Yamin J, Dockery S, Harrison DG. Regulation of endothelial nitric oxide synthuse mRNA, protein, and activity during cell growth. Am J Physiol 1994; 267: C1381-1388.